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Abstract
Background: Genetic screening to identify carriers of autosomal recessive diseases has become an integral part of
routine prenatal care. In spite of the rapid growth of known mutations, most current screening programs include
only a small subset of these mutations, and are performed using diverse molecular techniques, which are generally
labor-intensive and time consuming. We examine the implementation of the combined high-throughput technologies
of specific target amplification and next generation sequencing (NGS), for expanding the carrier screening program in
the Israeli Jewish population as a test case.
Methods: We compiled a panel of 370 germline mutations, causing 120 disorders, previously identified in affected
Jewish individuals from different ethnicities. This mutation panel was simultaneously captured in 48 samples using a
multiplex PCR-based microfluidics approach followed by NGS, thereby performing 17,760 individual assays in a single
experiment.
Results: The sensitivity (measured with depth of at least 50×) and specificity of the target capture was 98 and 95 %
respectively, leaving minimal rate of inconclusive tests per sample tested. 97 % of the targeted mutations present in
the samples were correctly identified and validated.
Conclusion: Our methodology was shown to successfully combine multiplexing of target specific primers, samples
indexing and NGS technology for population genetic screens. Moreover, it’s relatively ease of use and flexibility of
updating the targets screened, makes it highly suitable for clinical implementation. This protocol was demonstrated in
pre-conceptional screening for pan-Jewish individuals, but can be applied to any other population or different sets of
mutations.
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Background
Genetic screening to identify carriers of recessive dis-
eases (also known as preconception, premarital, prenatal,
or reproductive screening) aims to detect couples at risk
for transmitting hereditary genetic diseases to their off-
spring. The purpose of such screening is to provide the
prospective parents the opportunity to make informed
decisions regarding their reproductive options or the use
of early interventions (when available). From a public
health perspective, carrier screening programs reduce
the incidence of genetic diseases, and are cost-effective
from medical expenditure aspect.
The introduction of NGS platforms in recent years en-
ables DNA sequencing at an unprecedented yield and
low cost. It is clear that this technology will become the
method-of–choice for any clinical genetic testing pro-
gram and it holds the potential of expanding the current
screening programs for reproductive choices, in a similar
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manner that mass spectrometry has enabled screening
of newborns for metabolites [1]. Despite the feasibility of
sequencing entire exomes and genomes, such an ap-
proach is still not affordable or applicable for population
screening, in which thousands of samples must be ana-
lyzed and unambiguous results must be obtained auto-
matically in a timely manner. Thus, for the foreseeable
future, a targeted re-sequencing method is still required.
Moreover, the screening techniques chosen should be
flexible and scalable, in order to keep up with the new
genetic discoveries and rapid growth of mutation
databases.
In this work we explored the feasibility of microflui-
dics technology for target capture, followed by NGS to
expand carrier screening for reproductive purposes
(Fig. 1). The Jewish population in Israel was chosen as a
test case. Carrier screening in the Jewish population for
reproductive purposes has been carried out for decades.
Since the first preconception carrier screening program
for Tay Sachs disease was introduced for Ashkenazi Jews
in the 1970s [2], additional common mutations for other
severely debilitating diseases in the Jewish population
were identified, and have been introduced into screening
panels [3–5]. As a result, to date, the birth of affected
children with these diseases is rare, and the screening
programs have essentially become the “standard of care”,
administered either premarital, before conception, or
during the pregnancy.
An updated catalog of disease-causing mutations
found in Jewish population contains more than 1000 dif-
ferent mutations responsible for hundreds disorders
(http://server.goldenhelix.org/israeli/) [6]. Yet, currently
in most centers in Israel, genetic testing is offered for
only a limited subset of these (~30 diseases). The major
limitations for introducing new mutations into screening
panels are financial and technological constraints, such
as current laboratory techniques, human labor and test
execution time.
The official recommendations for genetic screening in
Israel from the Israeli Society of Medical Genetics [7]
and the Israeli Ministry of Health (MOH) [8] (and its
public funding) are largely based on the frequencies of
the mutations in the population (i.e. testing is prioritized
for more common mutations and avoided for the rarer
ones), and the screening is performed in an ethnic-
dependent manner (i.e. different mutation panels for
Ashkenazi Jews, Jews originating from North Africa,
Jews from Iraq, etc.).
However, over the past decades, the inter-ethnic mar-
riage rate has increased among the Jewish population in
Israel [9], and thus, choosing the relevant set of genetic
disorders for each couple from a growing list of available
tests, is becoming an impractical task.
The transition to high throughput technology-based
screening will most probably obviate both the mutations’
frequency criteria and the ethnicity-dependent recom-
mendations applied today, as was also acknowledged in
the new ACMG policy [10]. In this study, we provide
proof-of-concept for combining high-throughput tech-
nologies for targeting and sequencing a set of hundreds
known mutations, tailored to a specific population, to be
use in pre-conception carrier screening.
Methods
Target selection and compiling a mutation panel set
We compiled an updated comprehensive list of disease-
causing mutations in the Jewish population from data
provided by the Department of Community Genetics at
the Israeli Ministry of Health (as of Oct 2011). In the
targeted panel we included mutations for Autosomal re-
cessive (AR) or X –linked disorders, in which genetic
testing can identify couples at risk, and is likely to influ-
ence parental decisions regarding the pregnancy or the
clinical management of the newborn.
The online resources used for clinical evaluation in-
cluded the booklet “Mendelian disorders among Jews”
from the MOH website [8], “OMIM” [11] and “GeneRe-
views” at the NCBI website [12] Human Gene Mutation
Database (HGMD) [13], and relevant literature.
More than half of the mutations in the panel were
described in non-Ashkenazi patients from various
countries of origin. This set of mutations better re-
flects the current Israeli population, where Jews of
Fig. 1 The general workflow of this study which contains four principal steps: I. Data acquisition and design - creating the panel of mutations to
be targeted and designing specific primers and their multiplexing, II. Experimental procedures for target capture (using Fluidigm microfluidics
device) and sequencing (MiSeq platform), III. Bioinformatics analysis, mutation identification and validation and IV. Providing final report with the
mutations identified in each sample
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non-Ashkenazi origin comprise more than half of the
Jewish population (personal communication from the
Israeli MOH).
While some of the listed mutations have clear support
for being founder mutations (i.e. were identified in sev-
eral unrelated families), a large proportion were found
only in single families, and are currently regarded as
“private” mutations. However, we could not exclude the
possibility that they do exist (with lower frequencies) in
other individuals, and therefore we included them in the
panel. The final panel comprised of 370 mutations of
both single nucleotide variants (SNVs) and small inser-
tions and deletions (indels) in 148 genes associated with
120 disorders (Additional file 1).
Two of the mutations were substitutions of the same
genomic nucleotide to different alternative alleles (both
resulting in pathogenic mutations): p. R261P and
p.R261Q in the PAH gene and p.P339H and c.1016insC
in the CYBB gene. For the analysis of coverage depth,
each of the pairs were counted as one thus in total we
had to target 368 genomic positions for 370 mutations.
We also included in the panel four mutations of large-
rearrangements (deletion or insertion of up to tens of
Kb), with characterized genomic breakpoints, but these
were eventually excluded from the final analysis. The
genomic positions of all mutations were verified, includ-
ing the precise position of breakpoints in gross inser-
tions and deletions.
Primer design and multiplexing
To capture the genomic positions of the mutation list,
345 primer-pairs were designed and multiplexed into 45
sub-groups containing 1-12 primer pairs in each pool
using Fluidigm custom primer design service. To test
the ability to capture and sequence large rearrange-
ments, four primers-pairs were designed to span the
breakpoints of four mutations of large deletions or inser-
tions. These primers were expected to capture the ab-
normal chimeric products that exist only in carriers’
genomes (See examples in Additional file 2).
The primers multiplex algorithm (Fluidigm Co.) evalu-
ated the primer-primer interactions in order to minimize
the generation of undesirable PCR products, but to
maximize PCR specificity and efficiency. The major con-
siderations were to avoid combining primer pairs that
produce PCR products that overlap or are separated by
less than 5 kb, have high variability of GC content or are
not within 20 % of the average size. Amplicon lengths
were between 64 and 200 bps, with one outlier amplicon
of 418 bp designed for a large deletion mutation (6.7 kb
deletion in PAH gene). 54 mutations were designed to
be capture by multiple primer pairs, and 49 amplicons
covered multiple mutations.
DNA samples
The study was approved by the ethics committee of
Sheba Medical Center, Israel.
We obtained genomic DNA samples from 43 healthy
anonymous carriers of various genetic disorders. These
carriers were previously identified by traditional genetic
assays, and were used as positive controls to examine
the method. We included eight biological replicates (dif-
ferent samples that carry the same mutation) and four
technical replicates (the same sample tagged with two
different barcodes). The control samples were chosen to
include all types of genetic variations: 34 single nucleo-
tide substitutions (SNVs), 16 small indels, and five gross
re-arrangements, all analyzed in a blinded manner
(Table 1, “Knowns”).
Target capturing, library preparation and high-throughput
sequencing
Genomic DNA templates were amplified using the 48.48
Access Array IFC, according to the manufacturer’s in-
structions (Fluidigm). Briefly, 48 DNA samples were
combined with the 48 multiplex primers pairs on a
microfluidic IFC-chip. The IFC-chip was loaded with
PCR reagents using the Access Array pre-PCR controller
loading script and upon completion it was transferred to
a thermocycler. After amplification, pooled amplicons
from each of the 48 DNA templates were harvested
using Access Array post-PCR controller harvesting
script, and used as input for the subsequent off-chip
PCR reactions, in which each mini-library underwent
tagging with sample specific barcodes and attachment of
sequencing platform-specific adapters. The output li-
braries were purified using Qiagen PCR purification kit
and analyzed on an Agilent DNA1000 BioAnalyzer chip.
The purified combined libraries were sequenced using
MiSeq 150 bps pair-end protocol, according to the man-
ufacturers’ standard instructions.
Bioinformatics analysis
MiSeq sequencing data was de-barcoded to samples by
the Illumina BaseSpace server.
Alignments to the human genome (hg19) were per-
formed with BWA version 0.7.416, applying the mem
argument. Depth calculations per target and sample
were done with the DepthOfCoverage tool of the
GATK toolkit [14].
Three samples were excluded from further analysis of
variant calling and depth of coverage statistics: sample 2
and sample 27 had the lowest reads counts (35,142 and
118 reads, less than 1 % of reads in each of the other
samples), pointing to poor DNA quality or technical pip-
etting problem during library preparation; sample 36
was excluded due to insufficient coverage of large num-
ber of targets (44 targets with less than 10X), possibly
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Table 1 Summary of all mutations identified in the experiment
“Knowns”
Sample Gene Mutation Detected
S3 HEXA c.1278insTATC √
S6 CFTR p.F508 del √
S7 DYSF c.1624delG √
S8 FANCA c.2172-2173 + G √
S9 GBA p.84dupG √
S10 GJB2 c.167DelT √
S10 CFTR p.N1303K √
S11 GJB2 c.35delG √
S11 PAH A403V √
S11 ATM p.103C > T √
S12 GJB2 51_62del12ins1 √
S13 HEXA c.1278insTATC √
S13 SMARCAL1 IVS4 -2 A > G √
S14 HEXA p.F304/305del √
S15 SPMD1 p.R610del √
S15 PEX6 p.A809V √
S16 BCKDHB p.R183P √
S17 CERKL IVS1 + 1G > A √
S18 CFTR c.405 + 1G > A √
S19 CFTR p.G542X √
S20 CFTR p.G85E √
S21 CFTR p.W1282X √
S22 FANCC IVS4 + 4A > T √
S23 G6PC p.R83C √
S24 GBA c.115 + 1G > A xa
S25 GBA p.N370S √
S25 GBA p.V394L √
S25 PEX6 p.A809V √
S26 GBA p.R496H x
S28 CFTR p.Q359K + p.T360K √
S30 IKBKAP c.2204 + 6 T > C √
S31 HEXA p.G269S √
S32 TMEM216 p.R73L √
S33 HEXA IVS12 + 1G > C √
S34 HEXA p.R170Q √
S35 SPMD1 p.L302P √
S38 SPMD1 p.R496L √
S39 HEXA p.G250V √
S40 ATM p.103C > T √
S41 CFTR p.N1303K √
S42 GJB2 c.167DelT √
S42 CFTR p.N1303K √
S43 HEXA c.1278insTATC √
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due to technical microfluidics malfunction in specific
wells of the Access Array.
Single nucleotide variants (SNVs) and small indels
were identified with the GATK toolkit version 3.1.1
with default parameters (including realignment and
recalibration steps) [14]. Variants detected in technical
replicates were mostly identical, and almost all
discordant ones were in poorly covered positions (DP
< 10) in one of the duplicates. Variant Call Format
(VCF) files were then intersected with a list of posi-
tions of the mutations of interest. For small insertions
or deletions, a search within adjacent genomic inter-
vals was performed, and positions were manually cu-
rated as needed.
Table 1 Summary of all mutations identified in the experiment (Continued)
S44 DYSF c.1624delG √
S45 GJB2 51_62del12ins1 √
S46 CFTR p.N1303K √
S47 GJB2 c.35delG √
S47 PAH p.A403V √
S47 ATM p.103C > T √
S48 CFTR p.Y1092X √
Large Rearrangements
S1 GALT Del 5Kb √b
S4 PAH Del 6.7Kb √b
S3 MAK Ins353bp √b
S29 MAK Ins353bp √b
S32 MAK Ins353bp √b
“Unknowns”
Sample Gene Mutation validated
S3 CLRN1 p.N48K √
S3 ASPA p.E285A √
S7 AMN c.208-2A > G √
S17 SAMD9 p.R344X √
S18 GUCY2D c.389delC NA
S18 SERPINA1 p.E342K √
S18 SERPINA1 p.E264V √
S22 GJB2 p.V37I √
S31 ABCC8 c.3989-9G > A √
S31 PEX6 p.A809V √
S33 SPMD1 p.R496L √
S39 FANCC IVS4 + 4A > T √
S40 CFTR p.L997F NA
S40 FAM161A c.1355_6delCA √
S44 EYS p. Thr135LeuX25 √






aIdeantified manually with 26 % mutant allele
bdetected by finding exact match of chimeras sequences (explained in the Methods)
cfound as homozygous
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Variants detection criteria were minimal depth of
coverage (DP) of at least 50X and mutant allele percent-
age between 30 and 70 % for calling heterozygotes.
Mutations of large re-arrangements were detected by
identifying reads that align to mutant (chimeric) junction
reference sequence (could be captured only in samples
of carriers, see Additional file 2).
Validation of mutations
Novel and unexpected mutations that were identified in
the experiments (i.e. not previously known to be present
in the samples) were validated by Sanger sequencing in




Forty-eight DNA samples were captured for 368 gen-
omic positions (of 370 mutations) using the combined
high-throughput methods of microfluidics based multi-
plex PCR and NGS.
Sequencing the captured library with Illumina’s MiSeq
yielded a total of 5.4Gb with quality score of ≥Q30 (i.e.
sequencing error probability of 1 in 1000) in 92.1 % of
bases. 33,241,984 reads could be assigned to specific
samples by their barcodes. The average reads count was
692,541 per sample (range 392,815-1,455,638, excluding
two samples, see methods for details).
Average alignment rate to the human genome was
99.8 % per sample (range 96–100 %), with 95 % of reads
mapping to the expected amplicons, indicating high spe-
cificity of the primer design and capture procedure. 365
of 368 (99 %) genomic positions of the targeted muta-
tions were covered by at least 1 read, indicating success-
ful target capture by nearly all primer-pairs.
As the purpose of the experiment is to detect hetero-
zygote carriers of these mutations, sufficient coverage at
the mutation genomic position must be achieved. After
excluding three samples due to technical problems (see
Methods), the sensitivity of the capture protocol was
very high, as 358 of 368 (97 %) of the targeted genomic
positions had an average depth per sample of at least
150X, with more than 50X in all samples (Fig. 2).
The target capture with the multiplexed microfluidics
PCR technology enabled to essentially perform 16,650
independent assays in this experiment (where “assay” de-
fined as determining the presence of a single mutation
in a specific sample)., Reassuringly, the average depth of
an assay in our experiment was 2511X, with 98 % of the
assays covered by at least 50 - reads. The depth of cover-
age of most targets was uniform across the samples
(Fig. 3).
From the tested individuals (single samples) aspect, an
effective and well-designed high-throughput carrier test
should have minimal inconclusive results, i.e. number of
mutations that cannot be confidently identified due to
low coverage (under a pre-defined threshold). Excluding
the technically failed samples (see Methods), the min-
imal percentage of conclusive tests, with DP threshold of
at least 50X in a sample, was 98 % (360/368) showing
high completeness also per each sample analyzed.
Of note, most of the low covered targets were consist-
ent across samples, indicating that better primer design
might increase their capture efficiency.
Variant detection
To assess the ultimate goal of this protocol -its capability
to detect the mutations of interest- we used 40 samples
of known heterozygote of 50 different mutations (both
SNVs and indels). These samples were previously identi-
fied by traditional methods routinely applied for carrier
screening.
The samples were blindly screened using GATK vari-
ant calling pipeline, and 48 (96 %) of these mutations
Fig. 2 Average Depth per sample for each targeted mutation in ranked order (logarithmic scale). 353 out of 368 (99 %) mutation positions were
covered by an average at least 50X in a sample. Four mutations with average of zero coverage are not presented in the graph
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were successfully called in their expected samples and in
heterozygotes state (Table 1, “Knowns”). The two false
negatives were mutations in the GBA gene (R496H and
c.115 + 1G > A), causing Gaucher disease. Identifying
mutations in this gene has been recognized as problem-
atic due to the presence of the paralogues pseudogene
GBAP1 [15, 16]. The high similarity between GBA and
GBAP1 pose difficulties in specific capture and accurate
mapping of reads, and challenges mutation detection, es-
pecially where GBAP1 variants can be confused with
GBA mutations [17]. For example, in the c.115 + 1G > A
mutation, the mutated allele (A) corresponds to the ac-
tual normal reference sequence of the pseudogene, so
that reads originated from the GBAP1 can be identical
to ones derived from carrier with mutated GBA. Manual
inspection for this mutation had revealed that the mu-
tant allele is present with allele frequency of 26 % at the
sample of a known carrier, as expected if the reads from
GBA and GBAP1 were captured in even ratio.
Nevertheless, we correctly identified other mutations
in this gene (e.g.: p.84dupG in sample 9, p.N370S and
V394L in sample 25) captured by other amplicons, prov-
ing that with careful primer design, adjusting read length
and ascertainment of phasing during the bioinformatics
analysis, mutations in such genes can be identified.
In addition to the expected mutations described
above, we detected 64 additional variants from the tar-
get list that were not previously identified in the sam-
ples (Table 1,”Unknowns”). 49 of these were accounted
for by four substitutions, each identified in multiple
samples: p.G5R in LIPA.p.A10S in TRMU, p.G5R in
LIPA p. R76K in MYOC and p.G185S in ACADS which
were identified in 7,8,11 and 23 samples respectively; in
some samples they were called as homozygous
(Table 1,”Unknowns - variants with high incident”).
These observations support their re-classification as
common and benign polymorphisms, and we suggest
that they should not be included in future versions of
the mutation panel. The other 15 unexpected muta-
tions were found each in a single sample; 13 out of 13
were validated by Sanger sequencing or other methods.
In total, we were able to validate 61/63 (97 %) of the
mutations that were identified in the experiment. The
Average DP in these mutations was 519X and the aver-
age percentage of mutant allele was 49 % (range 36–
61 %, Additional file 3).
Finally, we also tested the ability of the capture proto-
col to identify mutations of large re-arrangements with
known breakpoints, using five samples of carriers and
special designed primers. We successfully identify reads
that aligned to mutant junction reference sequences in
those samples, proving that such mutations type could
also be included in the panel (see examples in Additional
file 2). However, as these mutations were called with in-
sufficient depth, it requires further calibration.
Discussion
We explored the feasibility of coupling microfluidics
technology for target capture with NGS as a fast and
cost-effective method for performing prenatal carrier
screening of the Israeli Jewish population. Our protocol
enabled performing ~17,000 assays in single experiment,
in each we aimed to determine the presence of a specific
mutation in a specific sample. The results of the pilot
study presented here were promising in both aspects of
Fig. 3 Heat map showing the depth of coverage of each mutation in each of the samples. A matrix of 17760 assays (368 mutation positions X 48
samples) is presented with color coded of red for less than 100X (our defined threshold) and white to purple gradient for more than 100X from
low to high coverage, respectively. The mutations are presented in ranked order by their average sample depth. Marked with arrows are the
three samples that were excluded from analysis due to technical problems (see Methods)
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target capture performance and the accuracy of muta-
tion detection.
The capture efficiency was very high as 97 % all of the
targeted mutation’ positions were captured with at least
50X in all samples (excluding the three faulty samples).
The sensitivity, measured as the percentage of mutations
that were covered in adequate depth (50X) to enable re-
liable variant identification, was 98 % both per individual
sample tested and globally, i.e. the total assays produced
on the chip. This minimizes the need to repeat samples
or perform supplemental analysis by other methods such
as Sanger sequencing. Finally and most importantly, we
were able to detect 96 % all mutations present in the
positive control set, and validate all the newly discovered
ones in the validation set.
One of the major advantages of the microfluidics de-
vice is the lack of potential cross hybridization, which
was reflected in the very low proportion of off-target
reads (high specificity). Another advantage of this target
capture technology is its dynamism and flexibility. Un-
like fixed genotyping methods, such as array-based
hybridization probes [18], the panel set can be easily up-
dated by changing the composition of primers in the
microfluidics device. New mutations are constantly been
discovered, and the panel can be adapted to keep pace
with these findings.
Undoubtedly, NGS is becoming the method of choice
for performing genetic testing in a clinical setting. Other
studies utilizing NGS for carrier screening for AR dis-
eases have been published. Bell et al. captured and se-
quenced a subset of the exome (containing only genes
that were previously associated with AR diseases) [19]
and Umbarger et al. focused on sequencing the entire
coding region of 15 genes [20]. In contrast, we
intentionally focused on a specific set of mutations. In
our view, although the cost of sequencing entire exomes
or genomes is constantly dropping, there are several ad-
vantages in using a targeted approach.
First, in large population screening, such as prenatal
carrier screening in Israel, tens of thousands of samples
are tested per year, and results must be obtained auto-
matically and in a timely fashion. For reliable variant
calling that meets clinical standards, sequencing data of
both high quality and depth is required. Achieving these
parameters in large genomic regions (such as exomes or
genomes) and in large population samples is not yet
cost-effective. Apart from the sequencing itself, there are
also costs involving the computational burden of analyz-
ing and storing large data sets, providing additional ad-
vantage to approaches that generate a relatively low and
manageable amount of data.
Second, the fine-targeted approach is highly suitable
for screening genetically homogenous or isolated popu-
lations, such as the Jewish individuals in Israel, in which
known mutations in specific genes account for the ma-
jority of the carriers [21, 22].
Third and most fundamental, is the concern regarding
ambiguous results. In any method that is not con-
strained to identifying already known mutations, the
possibility of identifying variants with uncertain signifi-
cance (VUS) is inevitable. Determining the biological
and clinical significance of such variants is in many in-
stances difficult and may yield inconclusive results. Not
every presumed loss-of-function variant has disease-
causing potential even in well annotated Mendelian
genes, such as CFTR [23] or HEXA [24]. Moreover, elu-
cidating VUS requires a personalized approach to data
interpretation, which is beyond the primary purpose of
large population screening, and may impose major diffi-
culties for healthcare providers that have to convey the
genetic information to the prospective parents. While
broader-scaled sequencing is advantageous in a research
setting, or in clinical testing of affected individuals, it
still lacks sufficient clinical validity and utility for screen-
ing healthy individuals. In our view, clinical screening
should identify only variants that are unequivocally dis-
ease associated and whose detection in carrier screening
is expected to aid in reproductive decisions or lead to
early intervention. In their recent policy statement on
expanding prenatal/preconception carrier screening with
high-throughput technologies, the American College of
Medical Genetics has raised these concerns and stated
that the tests should “include specific citations that sup-
port inclusion of the mutations for which screening is
being performed” [10].
For these reasons, we suggest that for the purpose of
pre-conception screening, a fine targeted method is ne-
cessary, and have included in our panel only mutations
that were previously reported to be disease causing.
In this mini-cohort of 48 samples, we have identified
four variants that are unlikely to be associated with any
pathology. When compiling the mutation panel set,
these variants were included because previous publica-
tions described them as disease-associated mutations.
Two variants (p.A10S in TRMU and.G185S in ACADS)
also appear in HGMD [13], and are flagged as “clinically
associated” in dbSNP, p.R76K in MYOC was believed to
contribute to glaucoma in a di-genic inheritance [25]
and p.G5R in LIPA was shown in a functional assay to
cause reduced enzymatic activity [26]. These variants
were highly prevalent in our sample set, were identified
as homozygous in some of the samples, and are also
present in 1000 Genomes with minor allele frequency of
at least 10 %. Therefore, we suggest that these variants
should be re-evaluated and considered as benign poly-
morphisms, and be excluded from future panels. Similar
findings in other reported mutations were also observed
by Bell et al [19], highlighting the need to improve
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databases of clinically associated variants. Nevertheless,
these findings illustrate the strength of our screening
protocol. By simultaneously screening dozens of samples
for each of the mutations, rapid information about the
frequencies of all tested mutations will accumulate, and
this in turn can help to correct such misinterpretations
and to optimize screening recommendations.
Before implementing our protocol into clinical care, a
few improvements are required. First, mutations and dis-
orders included should be updated to be compatible with
the latest professional guidelines and databases. Second,
for the poorly covered mutations and the large rearrange-
ments primers should be re-designed. Third, redundant
amplicons for each mutation can be introduced to
minimize technical capture failures. Fourth, the bioinfor-
matics analysis for mutation detection should be fine-
tuned, especially in challenging genomic regions such as
genes which have pseudogenes. In addition, In light of the
excessive depth achieved in our experiment for some of
the mutations, further multiplexing of primers for add-
itional mutations and/or increasing the number of sam-
ples in the parallel sequencing can be considered, to
further reduce the cost per sample and per mutation.
Conclusions
This is a proof-of-concept study designed to perform
large pre-conception population screening for thousands
of genetic tests in single experiment, without comprom-
ising on high confident of variant detection.
Our experimental system is practical and cost-
effective, balancing the high-throughput potential of the
latest cutting-edge technologies and the evidence-based
knowledge that is crucial in a clinical setting. The
current version of the protocol can be implemented into
a clinical service after few modifications. Moreover, this
approach can be also be customized for screening any
other populations with different mutation profile.
Additional files
Additional file 1: List of mutations included in the screening panel.
(XLS 61 kb)
Additional file 2: Examples of primer design and supporting reads for
the large-rearranged mutations. A. Deletion of ~5Kb in the GALT gene,
leading to Galactosemia. This mutation is composed of four breakpoints,
leading to two large deletions and one small insertion, and resulting in
the loss of almost the entire gene (adapted from Coffee et al. [27]). Vertical
arrows depict the breakpoints, and horizontal arrows mark the primers used
for capture. Primers 1 F +1R are used to capture the amplicon created in
the 5′ deleted region, and the 2 F + 2R primers are used to capture the
amplicon created in the 3′ indel region. B. Insertion of a 353 bp Alu element
into the MAK gene leads to Retinitis Pigmentosa (found by Tucker et al.
[28]). (PNG 69 kb)
Additional file 3: Total depth and percentage of mutant reads in the
validated heterozygote mutations (both previously knowns and
unknowns). As expected, the percentage of mutant alleles approximated
50 % for both SNPs and indels. (PNG 17 kb)
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